Cytosorbents Corporation

We'll be right back. Thank you. Thank you. Thank you. Thank you.

Good afternoon, ladies and gentlemen, and welcome to the Cytosorbent's first quarter 2026 earnings conference call. At this time, all lines are in listen-only mode. After the speaker's remarks, there will be a question and answer session. If you wish to ask a question during the Q&A session, please press star 1. As a reminder, this call is being recorded. And now I would like to turn the conference over to Pete Mariani, Chief Financial Officer. Please go ahead.

Thank you, Kathleen. And good afternoon, everyone. Welcome to CITUS Orbit's first quarter 2026 conference call. Joining me today is Dr. Philip Chan, our Chief Executive Officer, and Dr. Micah Steliagaris, our Chief Medical Officer. Before I turn the call over to Phil, I'd like to remind listeners that during the call, management's prepared remarks may contain forward-looking statements, which are subject to risks and uncertainties. Management may make additional forward-looking statements in response to your questions. Therefore, the company claims protection under the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results may differ from results discussed today. The forward-looking statements we make reflect our views and estimates as of today, May 13, 2026, and we assume no obligation to update these projections in the future as market conditions change. We encourage investors to review the risk discussed in our annual report on Form 10-K, filed with the SEC on March 30th, 2026, and as updated by the risks reported in our quarterly reports on Form 10-Q and in press releases and other communications to shareholders issued from time to time. During today's call, we will have an overview presentation covering the operating financial results for the first quarter of 2026, and provide a regulatory update on our process to obtain U.S. marketing approval for DrugsArb ATR. Following the presentation, we will open the lines to analysts for questions. And now, I'll turn the call over to Phil.